Compare ARK Next Generation Internet ETF (ARKW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Next Generation Internet ETF vs Sana Biotechnology Inc — how do they compare? ARK Next Generation Internet ETF trades at $150.74, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: ARK Next Generation Internet ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| ARKW | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $5.92 |
52-Week Low | $114.45 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $151.13, up 1.04% with strong technical momentum as moving averages signal bullish alignment. The ETF faces near-term headwinds from elevated AI infrastructure spending but maintains long-term growth positioning in next-generation internet technologies. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX confirms strong trend strength.
The ETF's outlook balances near-term capital expenditure pressures against long-term AI and technology exposure. Key risks include market skepticism toward growth stocks and concentration in volatile tech holdings. Analyst sentiment remains cautious with a Hold rating due to current market conditions despite the fund's innovative portfolio positioning.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
